Medipure Holdings Inc. Announces a Filing of its Provisional Patent for Proprietary Prodrug Platform for Various Therapeutics

Share Article

Company Continues Building Momentum Stepping Toward Adding to its Pipeline of Game-changing Pharmaceutical Products

News Image
These novel prodrugs are fast-acting and long-lasting molecules that complement Medipure’s drug discovery and development for our safe and effective endocannabinoid-targeted prescription medications.

Medipure Pharmaceuticals Inc. (“MPI”), a wholly owned subsidiary of Medipure Holdings Inc. (together with MPI, “Medipure” or the “Company”), a biopharmaceutical incubator committed to discovering and developing proprietary prescription drugs focused on the endocannabinoid system, is pleased to announce the submission of provisional patent application to the United States Patent and Trademark Office (“USPTO”) for MP-40X technology entitled “PROPRIETARY PRODRUG MOLECULES PRODUCTION METHOD AND USES THEREOF” U.S. 63/171,952. This invention relates to endocannabinoid targeting prodrug production and its therapeutic use in a novel delivery system. The said technology has provided a robust formulation platform to Medipure’s drug candidates to strengthen its therapeutic profile.

“We are very pleased to secure the intellectual property regarding our core therapeutic technology platform by this submission,” stated Boris Weiss, Chairman and CEO of Medipure Holdings Inc. “Apart from the apparent business reasons, I am especially excited and appreciative of our world-class team and collaborators, who have spent years developing and finetuning MP-40X to get it where it is today and that much closer to market.”

Founded in 2014 and based in Vancouver, Canada with laboratories in Croatia and India and other locations in the pipeline globally, Medipure develops its core products targeting specific disease areas including pain management, anxiety and mood disorders, dermatology, nausea, appetite, oncology, arthritis, and fatty liver disease. The Company’s goal is to cultivate pharmaceutical products that are non-addictive, have no side effects or toxicity, better efficacy at lower doses, and are absorbed by the body much quicker, and are more efficient with a longer life span than current drugs available in the marketplace.

“MP-40X is a unique therapeutic platform that comprises a series of endocannabinoid targeting molecules and is a fantastic addition to our portfolio of intellectual property,” stated Dr. Nihar Pandey, Medipure’s Chief Scientific Officer. “These novel prodrugs are fast-acting and long-lasting molecules that complement Medipure’s drug discovery and development for our safe and effective endocannabinoid-targeted prescription medications.”

Medipure continues with its patent applications for MP-40X in additional markets through the Patent Cooperation Treaty and will provide updates accordingly.


About Medipure
Medipure is a biopharmaceutical incubator committed to discovering and developing proprietary endocannabinoid system-based prescription drugs for targeted diseases by regulating specific molecular mechanisms.

Cautionary Note Regarding Forward Looking Information
This release includes certain statements that may be deemed “forward-looking statements”. All statements in this release, other than statements of historical facts, that address events or developments that the Company expects to occur, are forward-looking statements. Forward- looking statements are statements that are not historical facts and are generally, but not always, identified by the words “expects”, “plans”, “anticipates”, “believes”, “intends”, “estimates”, “projects”, “potential” and similar expressions, or that events or conditions “will”, “would”, “may”, “could” or “should” occur, negative of these terms, or other similar expressions intended to identify forward-looking statements. These forward-looking statements include, among other things, statements relating to: the expected medical benefits, viability, safety, efficacy, and dosing. Forward-looking statements are based on certain assumptions made by the Company in light of the experience and perception of historical trends, current conditions, and expected future developments and other factors it believes are appropriate, and are subject to risks and uncertainties. Although we believe that the assumptions underlying these statements are reasonable, they may prove to be incorrect, and we cannot assure that actual results will be consistent with these forward-looking statements. Given these risks, uncertainties, and assumptions, readers should not place undue reliance on these forward-looking statements. Whether actual results, performance, or achievements will conform to the Company’s expectations and predictions is subject to a number of known and unknown risks, uncertainties, assumptions, and other factors, including the inherent uncertainty of product development; our patent application may not be successful, third-party claims relating to misappropriation of their intellectual property; and our reliance on current early-stage research regarding the medical benefits, viability, safety, efficacy, and dosing of MP-30X. If any of these risks or uncertainties materialize, or if assumptions underlying the forward-looking statements prove incorrect, actual results might vary materially from those anticipated in the forward-looking statements.

Information contained in forward-looking statements in this news release is provided as of the date of this news release, and we disclaim any obligation to update any forward-looking statements, whether as a result of new information or future events or results, except to the extent required by applicable securities laws. Accordingly, readers should not place undue reliance on forward-looking statements or the information contained in those statements.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Doug Coupe
BOLD Communications Group
Email >
Visit website